OCS-05 is under clinical development by Oculis and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome). According to GlobalData, Phase I drugs for Neuromyelitis Optica (Devic’s Syndrome) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OCS-05’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OCS-05 overview

OCS-05 is under development for the treatment of multiple sclerosis, optic neuritis and neuromyelitis optica (Devic’s Syndrome), glaucoma. It is a new chemical entity. It is administered through topical, oral, intravenous and subcutaneous routes. The therapeutic candidate targets intracellular serine/threonine kinase SGK-2. It was also under development for the treatment of glaucoma, amyotrophic lateral sclerosis (ALS), Parkinson disease, Alzheimer's disease (AD), major depressive disorder, diabetic retinopathy and Macular Degeneration.

Oculis overview

Oculis operates as a clinical-stage biopharmaceutical company that offers topical treatments for acute, chronic back and front-of-the-eye ophthalmic diseases. Its pipeline product portfolio includes OCS-01 a topical treatment for diabetic macular edema, inflammation and pain, and cystoid macular edema; OCS-02 for uveitis and dry eye; OCS-05 for treating acute optic neuritis, glaucoma, and neurotrophic keratitis. Its Optireach helps in solubilizing technology to improve the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including anterior and posterior segments. The company has research operations in Reykjavik, Iceland. Oculis is headquartered in Lausanne, Waadt, Switzerland.

For a complete picture of OCS-05’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.